Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan Capital

Key Points

• Stoke Therapeutics received a "buy" rating from Chardan Capital with a target price of $24.00, indicating a potential upside of 48.22% from its current trading price.
• The company reported a quarterly earnings beat with EPS of ($0.40), better than analysts' expectations of ($0.57), alongside revenue of $13.82 million.
• Insiders have sold a total of 12,720 shares in the last ninety days, reflecting a 20.06% decrease in ownership by insider Barry Ticho after a recent sale.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Chardan Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $24.00 target price on the stock. Chardan Capital's target price suggests a potential upside of 48.22% from the stock's current price.

A number of other research firms also recently weighed in on STOK. Needham & Company LLC reissued a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a research note on Friday, July 18th. They issued a "buy" rating and a $30.00 target price for the company. Wedbush upped their target price on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday. Finally, HC Wainwright lowered their target price on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Stoke Therapeutics has an average rating of "Buy" and an average target price of $25.17.

Stoke Therapeutics Trading Up 19.7%

Shares of STOK traded up $2.66 on Wednesday, reaching $16.19. 1,125,730 shares of the company's stock were exchanged, compared to its average volume of 774,540. The stock has a market capitalization of $884.03 million, a P/E ratio of 20.37 and a beta of 1.15. The business has a 50 day moving average price of $12.16 and a two-hundred day moving average price of $10.01. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $16.45.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. The business had revenue of $13.82 million during the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a net margin of 26.33% and a return on equity of 19.08%. Equities research analysts predict that Stoke Therapeutics will post -2.01 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 6,471 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the completion of the transaction, the insider owned 25,782 shares in the company, valued at $258,593.46. This represents a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 12,720 shares of company stock valued at $140,095 in the last ninety days. 9.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. RTW Investments LP boosted its holdings in shares of Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after buying an additional 471,240 shares during the period. Baker BROS. Advisors LP grew its position in Stoke Therapeutics by 6.1% in the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company's stock valued at $51,111,000 after purchasing an additional 265,395 shares in the last quarter. Toronto Dominion Bank acquired a new stake in Stoke Therapeutics in the 4th quarter valued at $35,001,000. Vanguard Group Inc. lifted its position in Stoke Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company's stock worth $18,515,000 after buying an additional 53,004 shares in the last quarter. Finally, Siren L.L.C. boosted its stake in shares of Stoke Therapeutics by 12.4% during the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock worth $14,945,000 after buying an additional 247,347 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.